| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-96 |
Sentence |
denotes |
BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. |
| T1 |
0-96 |
Sentence |
denotes |
BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. |
| TextSentencer_T2 |
97-105 |
Sentence |
denotes |
PURPOSE: |
| T2 |
97-105 |
Sentence |
denotes |
PURPOSE: |
| TextSentencer_T3 |
106-228 |
Sentence |
denotes |
To determine the prevalence of BRCA1 and BRCA2 mutations in families identified in a breast cancer risk evaluation clinic. |
| T3 |
106-228 |
Sentence |
denotes |
To determine the prevalence of BRCA1 and BRCA2 mutations in families identified in a breast cancer risk evaluation clinic. |
| TextSentencer_T4 |
229-250 |
Sentence |
denotes |
PATIENTS AND METHODS: |
| T4 |
229-250 |
Sentence |
denotes |
PATIENTS AND METHODS: |
| TextSentencer_T5 |
251-447 |
Sentence |
denotes |
One hundred sixty-four families seeking breast cancer risk evaluation were screened for coding region mutations in BRCA1 and BRCA2 by conformation-sensitive gel electrophoresis and DNA sequencing. |
| T5 |
251-447 |
Sentence |
denotes |
One hundred sixty-four families seeking breast cancer risk evaluation were screened for coding region mutations in BRCA1 and BRCA2 by conformation-sensitive gel electrophoresis and DNA sequencing. |
| TextSentencer_T6 |
448-456 |
Sentence |
denotes |
RESULTS: |
| T6 |
448-456 |
Sentence |
denotes |
RESULTS: |
| TextSentencer_T7 |
457-574 |
Sentence |
denotes |
Mutations were identified in 37 families (22.6%); 28 (17.1%) had BRCA1 mutations and nine (5.5%) had BRCA2 mutations. |
| T7 |
457-574 |
Sentence |
denotes |
Mutations were identified in 37 families (22.6%); 28 (17.1%) had BRCA1 mutations and nine (5.5%) had BRCA2 mutations. |
| TextSentencer_T8 |
575-677 |
Sentence |
denotes |
The Ashkenazi Jewish founder mutations 185delAG and 5382insC (BRCA1) were found in 10 families (6.1%). |
| T8 |
575-677 |
Sentence |
denotes |
The Ashkenazi Jewish founder mutations 185delAG and 5382insC (BRCA1) were found in 10 families (6.1%). |
| TextSentencer_T9 |
678-805 |
Sentence |
denotes |
However, 6174delT (BRCA2) was found in only one family (0.6%) despite estimates of equal frequency in the Ashkenazi population. |
| T9 |
678-805 |
Sentence |
denotes |
However, 6174delT (BRCA2) was found in only one family (0.6%) despite estimates of equal frequency in the Ashkenazi population. |
| TextSentencer_T10 |
806-987 |
Sentence |
denotes |
In contrast to other series, the average age of breast cancer diagnosis was earlier in BRCA2 mutation carriers (32.1 years) than in women with BRCA1 mutations (37.6 years, P =.028). |
| T10 |
806-987 |
Sentence |
denotes |
In contrast to other series, the average age of breast cancer diagnosis was earlier in BRCA2 mutation carriers (32.1 years) than in women with BRCA1 mutations (37.6 years, P =.028). |
| TextSentencer_T11 |
988-1154 |
Sentence |
denotes |
BRCA1 mutations were detected in 20 (45.5%) of 44 families with ovarian cancer and 12 (75%) of 16 families with both breast and ovarian cancer in a single individual. |
| T11 |
988-1154 |
Sentence |
denotes |
BRCA1 mutations were detected in 20 (45.5%) of 44 families with ovarian cancer and 12 (75%) of 16 families with both breast and ovarian cancer in a single individual. |
| TextSentencer_T12 |
1155-1265 |
Sentence |
denotes |
Significantly fewer BRCA2 mutations (two [4.5%] of 44) were detected in families with ovarian cancer (P =.01). |
| T12 |
1155-1265 |
Sentence |
denotes |
Significantly fewer BRCA2 mutations (two [4.5%] of 44) were detected in families with ovarian cancer (P =.01). |
| TextSentencer_T13 |
1266-1360 |
Sentence |
denotes |
Eight families had male breast cancer; one had a BRCA1 mutation and three had BRCA2 mutations. |
| T13 |
1266-1360 |
Sentence |
denotes |
Eight families had male breast cancer; one had a BRCA1 mutation and three had BRCA2 mutations. |
| TextSentencer_T14 |
1361-1442 |
Sentence |
denotes |
CONCLUSION: BRCA1 mutations were three times more prevalent than BRCA2 mutations. |
| T14 |
1361-1442 |
Sentence |
denotes |
CONCLUSION: BRCA1 mutations were three times more prevalent than BRCA2 mutations. |
| TextSentencer_T15 |
1443-1733 |
Sentence |
denotes |
Breast cancer diagnosis before 50 years of age, ovarian cancer, breast and ovarian cancer in a single individual, and male breast cancer were all significantly more common in families with BRCA1 and BRCA2 mutations, but none of these factors distinguished between BRCA1 and BRCA2 mutations. |
| T15 |
1443-1733 |
Sentence |
denotes |
Breast cancer diagnosis before 50 years of age, ovarian cancer, breast and ovarian cancer in a single individual, and male breast cancer were all significantly more common in families with BRCA1 and BRCA2 mutations, but none of these factors distinguished between BRCA1 and BRCA2 mutations. |
| TextSentencer_T16 |
1734-1834 |
Sentence |
denotes |
Evidence for reduced breast cancer penetrance associated with the BRCA2 mutation 6174delT was noted. |
| T16 |
1734-1834 |
Sentence |
denotes |
Evidence for reduced breast cancer penetrance associated with the BRCA2 mutation 6174delT was noted. |